Actuate Therapeutics Inc (ACTU) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1 |
| Open | 1.04 |
| Day High | 1.04 |
| Day Low | 0.98 |
| 52-Week High | 8.49 |
| 52-Week Low | 0.9 |
| Volume | 135,022.45 |
| Average Volume | 375,348 |
| Market Cap | 24.4M |
| PE | -1.17 |
| EPS | -0.87 |
| Moving Average 50 Days | 1.26 |
| Moving Average 200 Days | 3.13 |
| Change | 0.02 |
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
GlobeNewswire Inc.
Mar 09, 2026 12:45 PM GMT
Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancersMechanisms of action support enhanced activity of GSK-3β plus RAS inhibitionPreclinical combination results expecte
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
GlobeNewswire Inc.
Mar 04, 2026 10:00 PM GMT
CHICAGO and FORT WORTH, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, d
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 24, 2026 1:45 PM GMT
CHICAGO and FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, di